AI-generated analysis. Always verify with the original filing.
Bolt Biotherapeutics, Inc. reported fourth quarter and full-year 2025 financial results, including collaboration revenue of $2.5 million and $7.7 million, respectively, R&D expenses of $5.0 million and $28.5 million, and a cash balance of $31.8 million as of December 31, 2025, expected to fund operations into 2027. The company provided a business update on BDC-4182 Phase 1 trial with initial data expected in 3Q 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
Results of Operations and Financial Condition. On March 12, 2026, Bolt Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial res
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated March 12, 2026. 104 Cover Page Interactive Data File (embedded
| Metric | Value | Basis |
|---|---|---|
| Collaboration revenue | $2.50 | GAAP |
| Collaboration revenue | $7.70 | GAAP |
| Research and development expenses | $4.99 | GAAP |
| Research and development expenses | $28.53 | GAAP |
| General and administrative expenses | $3.12 | GAAP |
| General and administrative expenses | $13.80 | GAAP |
| Loss from operations | $-7.09 | GAAP |
| Loss from operations | $-36.11 | GAAP |
| Net loss | $-6.63 | GAAP |
| Net loss | $-33.38 | GAAP |
| Net loss per share | $-3.84 | GAAP |
| Net loss per share | $-17.85 | GAAP |